EMA Recommends Revoking Amgen Rare-Drug Approval, Pressuring Stock

Key Facts

1The European Medicines Agency recommended revoking the marketing authorisation for Amgen's rare autoimmune disease drug Tavneos, citing a lack of benefits that outweigh its risks.

In a negative regulatory development for the rare-disease drug sector, the European Medicines Agency (EMA) recommended revoking the marketing authorisation for Amgen's (AMGN) Tavneos, a treatment for rare autoimmune diseases. The recommendation followed the agency's conclusion that the drug's benefits do not outweigh its risks, according to a Reuters report.

Tavneos accounts for a relatively small portion of Amgen's total revenue, but the decision highlights the regulatory risks facing rare-disease drugs, as the EMA demands clear evidence of a favorable benefit-risk balance. The move comes as Amgen faces pressure to bolster its pipeline following patent expirations on some of its key drugs.

Amgen shares (AMGN) closed at $352.82 on June 25, 2026, trading in a range of $350.06 to $359.10. The stock may face further pressure as investors await the company's official response and a potential appeal, making the $350 support level pivotal in the coming sessions.